Literature DB >> 26067951

Draft Genome Sequences of Clinical Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strain APS211 and Its Daptomycin-Susceptible Progenitor APS210.

David R Cameron1, Jhih-Hang Jiang1, Iain J Abbott, Denis W Spelman, Anton Y Peleg2.   

Abstract

To assess the genetic factors contributing to daptomycin resistance in Staphylococcus aureus, the draft genome of a clinically derived daptomycin-nonsusceptible isolate APS211 was generated and compared to the draft sequence of its susceptible progenitor strain APS210. Four genetic differences were identified including a previously described mutation within the mprF gene.
Copyright © 2015 Cameron et al.

Entities:  

Year:  2015        PMID: 26067951      PMCID: PMC4463516          DOI: 10.1128/genomeA.00568-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Daptomycin is a cyclic lipopeptide antibiotic that is increasingly relied upon for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections (1). Daptomycin-nonsusceptible strains (defined by a MIC > 1.0 µg/mL) have recently been described, however, the genetic mechanism behind the emergence of these strains is not completely understood (2, 3). We, and others, have performed whole-genome sequencing of daptomycin-exposed strains, identifying point mutations in numerous genes including those important for phospholipid metabolism (most notably the lysl-phosphatidylglycerol synthase, encoded by mprF), as well as the two-component regulatory system, walKR, and RNA polymerase subunits rpoB and rpoC (2, 4–6). In order to further understand the development of daptomycin resistance in S. aureus, we prepared the draft genome sequence of a daptomycin-susceptible strain, APS210 (daptomycin MIC 0.5 µg/mL), isolated from a patient with bacteremia and compared it to its daptomycin nonsusceptible derivative, APS211 (daptomycin MIC 4.0 µg/mL), that emerged after daptomycin treatment and therapeutic failure. Genomic DNA from APS210 and APS211 was prepared using a QIAGEN blood and tissue kit per the manufacturer’s instructions and sequenced using Illumina MiSeq (250-bp paired-end reads) generating 5,255,342 and 4,468,075 reads, respectively. Draft genomes were assembled de novo using CLC workbench (v6.0.2) with >1,000× coverage and each genome was annotated using the NCBI Prokaryotic Genomes Annotation Pipeline. The genome sequence of APS210 comprised 83 contigs (>500 bp in length, N50 = 74,505 bp) with a combined length of 2,906,880 bp, G+C content of 32.7%, and 2,859 predicted protein-coding regions. The sequence of APS211 comprised 72 contigs (>500 bp in length, N50 = 73,502 bp) with a combined length of 2,905,661 bp and G+C content of 32.7%. Both strains were sequence type (ST) 45 and staphylococcal cassette chromosome mec (SCCmec) type V (7). Comparison of the two genomes revealed four single nucleotide polymorphisms (SNPs) including a mutation that led to the previously described MprF amino acid substitution, S337L (2, 8). Two of the SNPs were predicted to be synonymous within hypothetical proteins (a predicted phage protein and a protein with similarity to N-acyl-l-amino acid amidohydrolase) and the final SNP was predicted to be intergenic. Defining the precise molecular mechanisms behind MprF-mediated daptomycin-nonsusceptibility in S. aureus is ongoing in our laboratory.

Nucleotide sequence accession numbers.

The whole-genome shotgun sequences of APS210 and APS211 have been deposited in DDBJ/EMBL/GenBank under the accession numbers JXUD00000000 and JXUV00000000, respectively.
  8 in total

1.  Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC.

Authors:  Teruyo Ito; Xiao Xue Ma; Fumihiko Takeuchi; Keiko Okuma; Harumi Yuzawa; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Authors:  Lisa Friedman; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Authors:  M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance.

Authors:  Soo-Jin Yang; Nagendra N Mishra; Aileen Rubio; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

6.  Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

Authors:  Satish K Pillai; Howard S Gold; George Sakoulas; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

7.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

8.  Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

Authors:  Anton Y Peleg; Spiros Miyakis; Doyle V Ward; Ashlee M Earl; Aileen Rubio; David R Cameron; Satish Pillai; Robert C Moellering; George M Eliopoulos
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

  8 in total
  5 in total

Review 1.  Deciphering the tRNA-dependent lipid aminoacylation systems in bacteria: Novel components and structural advances.

Authors:  Rachel N Fields; Hervé Roy
Journal:  RNA Biol       Date:  2017-11-03       Impact factor: 4.652

2.  Draft Genome Sequence of Methicillin-Sensitive Staphylococcus aureus ATCC 29213.

Authors:  Isha Soni; Harinath Chakrapani; Sidharth Chopra
Journal:  Genome Announc       Date:  2015-09-24

3.  Common Adaptive Strategies Underlie Within-Host Evolution of Bacterial Pathogens.

Authors:  Yair E Gatt; Hanah Margalit
Journal:  Mol Biol Evol       Date:  2021-03-09       Impact factor: 16.240

4.  Novel Daptomycin Tolerance and Resistance Mutations in Methicillin-Resistant Staphylococcus aureus from Adaptive Laboratory Evolution.

Authors:  Jordy Evan Sulaiman; Henry Lam
Journal:  mSphere       Date:  2021-09-29       Impact factor: 4.389

5.  Evaluating the ototoxicity of an anti-MRSA peptide KR-12-a2.

Authors:  Chung Man Sung; Hong Chan Kim; Yong Beom Cho; Song Yub Shin; Chul Ho Jang
Journal:  Braz J Otorhinolaryngol       Date:  2017-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.